Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Parkinson DiseaseThe primary purpose of this study is to establish a dosage of isradipine CR that is tolerable and demonstrates preliminary efficacy for utilization in future pivotal efficacy studies.
Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics
Parkinson DiseaseDyskinesiasThe purpose of this study is to study different kinds of dyskinesias in advanced Parkinson's disease appearing at different levels of levodopa infusion dose. The hypothesis is that different dyskinesias (dystonia, chorea) correlate to different levels of levodopa concentrations, as detected in plasma.
Antidepressant Effect of Deep Brain Stimulation in Parkinson's Disease Patients
Parkinson's DiseaseMajor Depressive DisorderThe purpose of this study is: To determine, in the context of a prospective clinical trial, whether stimulation parameters in PD patients treated with DBS, are associated with antidepressant effects. To determine whether these antidepressant effects are related to or independent of changes in the motor features of PD. To establish a computerized database that includes stimulation parameters and clinical parameters in PD patients treated with DBS. To develop a computer-assisted decision making protocol for programming of DBS parameters in both depressed and non-depressed PD patients.
Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease
Parkinson's DiseaseTo compare the efficacy of BF2.649 over placebo (12 week Double-Blind Phase) and assess the long term safety and the efficacy maintenance(9 months Open-Label Extension Phase) of BF2.649 in the improvement of excessive daytime sleepiness in patients diagnosed with Parkinson's Disease.
A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients...
Parkinson's DiseaseThis study is conducted to evaluate the safety and tolerability of the drug product sNN0031, containing Platelet Derived Growth Factor (PDGF), when administered directly into one of the fluid filled cavities in the brain using an implanted catheter and an implanted SynchroMed® II pump. Patients with a diagnosis of Parkinson's disease will be enrolled.
A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and...
Parkinson's DiseaseThis study will investigate the effect of TCH346 compared to placebo in delaying the need for symptomatic treatment with dopaminergic agents
SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations
Advanced Stage Parkinson's DiseaseThis study is a multicenter, randomized, double blind, parallel group study of 3 months' treatment with SLV308 administered as a monotherapy in patients with advance stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants...
Parkinson DiseaseThis is a randomized, placebo-controlled, 3-period crossover, balanced, single-site, third party-blind study of preladenant (SCH 420814) in participants with Parkinson disease (PD) to be conducted in conformance with Good Clinical Practices. This trial will investigate the effects of single doses of preladenant and placebo on the dyskinesia and antiparkinsonian actions of a levodopa infusion. The study will examine 10 mg ("low dose") or 100 mg ("high dose") study drug, given as single, oral administrations in conjunction with intravenous (IV) levodopa infusion and oral carbidopa.
Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease
Depressive DisorderParkinson DiseaseThis study will evaluate the effectiveness of atomoxetine in reducing symptoms of depression in people with Parkinson's disease.
Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
DyskinesiasParkinson's Disease1 moreLong term safety and efficacy (12 months) of levodopa-carbidopa intestinal gel.